Search
Mediwound Ltd
MDWDAdd to Watchlist
15.160USD
+0.340+2.29%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
194.84MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Mediwound Ltd is 8.33, ranking 43 out of 157 in the Pharmaceuticals industry. The average price target is 32.00, with a high of 39.00 and a low of 25.00.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
30.167
Target Price
+100.04%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
177
Total
6
Median
8
Average
Company name
Ratings
Analysts
Mediwound Ltd
MDWD
6
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
36
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Mediwound Ltd's expected revenue for the next quarter?
Mediwound Ltd's expected revenue is 2.59M.
What is Mediwound Ltd's price target?
Analysts forecast that Mediwound Ltd's price target is USD 32.00, with the highest forecast at USD 39.00 and the lowest forecast at USD 25.00.
How have Mediwound LtdMDWD's recent earnings per share performed?
The market expectation was USD -0.23, while Mediwound LtdMDWD's earnings per share (EPS) for the previous quarter was USD -0.56. EPS for the next quarter is expected at USD -0.76.
What is the analyst rating for Mediwound Ltd?
Based on the ratings of Mediwound Ltd's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.